Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

2008 Schmitz, 2002, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, 359, 2065, 10.1016/S0140-6736(02)08938-9 Martinez, 2013, Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation, Ann Oncol, 24, 2430, 10.1093/annonc/mdt206 Arai, 2013, Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant, Leuk Lymphoma, 54, 2531, 10.3109/10428194.2013.798868 Younes, 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 30, 2183, 10.1200/JCO.2011.38.0410 Cheah, 2016, Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes, Ann Oncol, 27, 1317, 10.1093/annonc/mdw169 Kuppers, 2009, The biology of Hodgkin's lymphoma, Nat Rev Cancer, 9, 15, 10.1038/nrc2542 Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855 Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Roemer, 2016, PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome, J Clin Oncol, 10.1200/JCO.2016.66.4482 Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, 471, 377, 10.1038/nature09754 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Yamamoto, 2008, PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma, Blood, 111, 3220, 10.1182/blood-2007-05-085159 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Ansell, 2015, Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039), Blood, 126, 583, 10.1182/blood.V126.23.583.583 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Pickard, 2007, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, 5, 70, 10.1186/1477-7525-5-70 Griffeth, 2005, Use of PET/CT scanning in cancer patients: technical and practical considerations, Proc (Bayl Univ Med Cent), 18, 321 Barrington, 2014, When should FDG-PET be used in the modern management of lymphoma?, Br J Haematol, 164, 315, 10.1111/bjh.12601